The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
News|Articles|December 9, 2021
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of December 9, 2021
Author(s)Sydney Jennings
Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
Advertisement
How many fully vaccinated Americans have received a booster dose?
According to the
How many people in the US have been vaccinated against COVID-19?
According to the CDC as of today, November 12, 2021, at 3:25 PM, EDT:
• 71.5% of total US population has received at least 1 dose
• 60.5% of total US population is fully vaccinated
• 60.5% of total US population is fully vaccinated
The 5 states/territories with the highest percentage of population fully vaccinated are:
1. Puerto Rico: 75%
2. Vermont: 74.5%
3. Rhode Island:74.3%
4. Maine: 73.7%
5. Connecticut: 73.1%
2. Vermont: 74.5%
3. Rhode Island:74.3%
4. Maine: 73.7%
5. Connecticut: 73.1%
How many cases of COVID-19 have been confirmed in the US?
According to the Johns Hopkins COVID-19 interactive map , as of today, December 9, 2021 at 4:22 PM, EDT, there have been:
• 49 621 791 confirmed cases and
• 794 020 deaths
• 794 020 deaths
The 5 states with the highest total confirmed cases are:
1. California: 5 145 071
2. Texas: 4 369 078
3. Florida: 3 741 058
4. New York: 2 809 240
5. Illinois: 1 877 213
2. Texas: 4 369 078
3. Florida: 3 741 058
4. New York: 2 809 240
5. Illinois: 1 877 213
Deaths: California has the highest number of deaths due to COVID-19 with 75 159 reported fatalities, followed by Texas with 74 452 and Florida with 61 789.
How many cases of COVID-19 have been confirmed globally?
Globally, there have been 268 401 535 confirmed cases, 5 285 559 deaths, and 8 323 691 667 vaccine doses administered.
Advertisement
Related to this article
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
Retatrutide trials report less knee osteoarthritis pain; ixekizumab plus tirzepatide shows exploratory ACR50 benefits in psoriatic arthritis.
Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Asundexian for Stroke Prevention After Ischemic Stroke or TIA
2
New Study Shows Menopause Undercoded in Primary Care, With Gaps by Race and Insurance
3
Contraindicated Hormone Therapy Prescribing Climbs in Primary Care
4
Retatrutide Phase 3 Trials Report Reduced Knee Osteoarthritis Pain
5